Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
2-APB (HB1208)
Description:IP3 receptor and store-operated channels (SOC) channel antagonist
Purity:>98%
Acamprosate calcium (HB0099)
Description:GABA receptor agonist and glutamatergic modulator
Purity:>98%
Amantadine hydrochloride (HB0109)
Description:Non-competitive NMDA receptor antagonist
Purity:>98%
(±)-Anatoxin A fumarate (HB2023)
Description:Potent nicotinic agonist. Apoptosis inducer.
Purity:>99%
Aniracetam (HB0116)
Description:Nootrophic AMPA receptor positive allosteric modulator
Purity:>98%